Trials / Completed
CompletedNCT03954834
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
A Randomized, Double-blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Three Tirzepatide Doses Versus Placebo in Patients With Type 2 Diabetes, Inadequately Controlled With Diet and Exercise Alone
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 478 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal for this study is to evaluate the efficacy and safety of tirzepatide versus placebo in participants with type 2 diabetes not under control with diet and exercise alone. The study will last approximately 47 weeks and may include about 15 visits.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tirzepatide | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2019-06-03
- Primary completion
- 2020-10-05
- Completion
- 2020-10-28
- First posted
- 2019-05-17
- Last updated
- 2021-10-20
- Results posted
- 2021-10-20
Locations
53 sites across 5 countries: United States, India, Japan, Mexico, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03954834. Inclusion in this directory is not an endorsement.